Joseph R. Wagner

Canadian Journal of Urology, Vol.29, No.1, pp. 10979-10979, 2022

Abstract This article has no abstract. More >

Peter J. Gilling¹, Neil Barber², Mohamed Bidair³, Paul Anderson⁴, Mark Sutton⁵, Tev Aho⁶, Eugene Kramolowsky⁷, Andrew Thomas⁸, Ronald P. Kaufman, Jr.⁹, Gopal Badlani¹⁰, Mark Plante¹¹, Mihir Desai¹², Leo Doumanian¹², Alexis E. Te¹³, Claus G Roehrborn¹⁴

Canadian Journal of Urology, Vol.29, No.1, pp. 10960-10968, 2022

Abstract Introduction: To determine if Aquablation therapy can maintain long term effectiveness in treating men with moderate to severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) with a baseline prostate volume between 30 and 80 mL at 5 years compared to TURP.
Materials and methods: In a double-blinded, multicenter prospective randomized controlled trial, 181 patients with moderate to severe LUTS secondary to BPH underwent TURP or Aquablation. The primary efficacy endpoint was reduction in International Prostate Symptom Score (IPSS) at 6 months. The primary safety endpoint was the occurrence of Clavien-Dindo persistent Grade 1… More >

Marco Frisenda^1,2,*, Stefano Signore¹, Giampaolo Delicato¹, Andrea Giovanni Martinelli¹, Andrea Cantiani¹, Marco Colafelice³, Antonio Tufano², Francesco Del Giudice², Michael L. Eisenberg⁴, Alessandro Sciarra², Vittorio Canale^1,2,*

Canadian Journal of Urology, Vol.29, No.2, pp. 11095-11100, 2022

Abstract This article has no abstract. More >

Gopal Narang, Jonathan Moore, Haidar Abdul-Muhsin, Scott Cheney, Mitchell Humphreys

Canadian Journal of Urology, Vol.29, No.2, pp. 11067-11074, 2022

Abstract Introduction: Holmium laser enucleation of the prostate (HoLEP) is an effective but underutilized option for the surgical management of benign prostatic hyperplasia (BPH). With low adoption, questions arise surrounding patients access to care. It is unclear whether patients undergoing HoLEP are local or specifically seek care from afar. We looked to determine the proportion of patients who traveled out-of-state for HoLEP treatment and the impact of travel on peri and postoperative metrics.
Materials and methods: We performed a retrospective cohort study evaluating patients that underwent HoLEP at a single institution from 2007-2019. Patient demographic, perioperative data, postoperative… More >

Sameer Thakker¹, James Wysock², Richard Matulewicz², Rozalba Gogaj², Herbert Lepor²

Canadian Journal of Urology, Vol.29, No.3, pp. 11128-11135, 2022

Abstract Introduction: Given the increasing interest in partial gland cryo-ablation as a treatment modality and the lack of data surrounding urinary and sexual outcomes after the procedure, the goal of this analysis was to assess functional outcomes following partial gland cryo-ablation (PGCA) stratified according to baseline severity of lower urinary tract symptoms (LUTS) and erectile function (EF). A secondary goal was to also determine if there were any clinical factors associated with significant change in LUTS and EF.
Materials and methods: Since 3/2017, all men undergoing primary PGCA were offered enrollment into an IRB-approved prospective outcomes registry. Men… More >

Amy Burns¹, Stephen Harrington², Suzanne Boltz¹, Ross M. Decter¹

Canadian Journal of Urology, Vol.29, No.5, pp. 11335-11339, 2022

Abstract Distal hypospadias is a common congenital urology anomaly for which numerous corrective procedures have been described. Over the last 40 years, the gold-standard operative technique for distal hypospadias has switched from the meatal advancement and glanuloplasty (MAGPI) procedure to the tubularized incised plate (TIP) urethroplasty. A modification to the MAGPI procedure, first described 30 years ago, is the M inverted V (MIV) glansplasty, which improved upon the MAGPI procedure to reduce instances of meatal retraction. The MIV glansplasty is unique compared to many commonly used procedures as it does not require a formal urethroplasty or More >

Iman Sadri^1*, Adel Arezki^1*, Ahmed S. Zakaria², Félix Couture³, David-Dan Nguyen¹, Nassim Bousmaha², Pierre Karakiewicz², Kevin C. Zorn²

Canadian Journal of Urology, Vol.29, No.5, pp. 11292-11299, 2022

Abstract Introduction: Incontinence after robot-assisted radical prostatectomy (RARP) significantly impacts quality of life. This study aims to compare the age-stratified continence outcomes in Canadian men undergoing RARP.
Materials and methods: A retrospective review was performed on a prospectively maintained database of 1737 patients who underwent RARP for localized prostate cancer between 2007 and 2019. Patients were stratified into five groups based on age: group 1, ≤ 54 years (n = 245); group 2, 55-59 years (n = 302); group 3, 60-64 years (n = 386); group 4, 65-69 years (n = 348); and group 5, ≥ 70 years… More >

Jonathan E. Heinlen

Canadian Journal of Urology, Vol.29, No.5, pp. 11291-11291, 2022

Abstract This article has no abstract. More >

Kassem S. Faraj¹, Weslyn D. Bunn², Victoria S. Edmonds², Mark D Tyson¹

Canadian Journal of Urology, Vol.29, No.5, pp. 11284-11290, 2022

Abstract Introduction: A comprehensive analysis on outcomes in the perioperative and pathological setting in patients with a prior diagnosis of prostate cancer has not been performed. The objective of this study is to describe the effect of prior prostate cancer treatment on perioperative and pathological outcomes after cystectomy.
Materials and methods: This was a retrospective review of all male patients who underwent cystectomy at our institution from 01/01/2007-01/01/2020. Patients who were previously diagnosed and treated for prostate cancer were identified and outcomes were assessed.
Results: In 525 male patients, 132 (25.1%) had a diagnosis of prostate cancer prior to… More >

YUNG-SUNG YEH^1,2,3, HSIANG-LIN TSAI^4,5, YEN-CHENG CHEN^4,6, WEI-CHIH SU^4,6, PO-JUNG CHEN^4,6, TSUNG-KUN CHANG^4,6,7, CHING-CHUN LI⁴, CHING-WEN HUANG^4,5, JAW-YUAN WANG^{4,5,6,8,9,10,*}

Oncology Research, Vol.30, No.2, pp. 65-76, 2022, DOI:10.32604/or.2022.026659 - 05 January 2023

Abstract The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7–20). Clinical outcomes, including response,… More >